Publications

  1. Wahner Hendrickson AE, Menefee ME, Hartmann LC, Long HJ, Northfelt DW, Reid JM, Boakye-Agyeman F, Kayode O, Flatten KS, Harrell MI, Swisher EM, Poirer GG, Satele D, Allred JB, Lensing JL, Chen A, Ji JJ, Zhang Y, Erlichman C, Haluska P, Kaufmann SH. A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors. Clin Cancer Res. 2017 Nov 14 [Epub ahead of print]
    View PubMed
  2. Geller JI, Perentesis JP, Liu X, Minard CG, Kudgus RA, Reid JM, Fox E, Blaney SM, Weigel BJ. A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111). Pediatr Blood Cancer. 2017 Nov; 64 (11) Epub 2017 Apr 27
    View PubMed
  3. Krieger CA, Cunningham JL, Reid JM, Langman LJ, Grothe KB, Clark MM, Dierkhising RA. Comparison of Bioavailability of Single-Dose Extended-Release Venlafaxine Capsules in Obese Patients Before and After Gastric Bypass Surgery. Pharmacotherapy. 2017 Nov; 37 (11):1374-1382 Epub 2017 Oct 10
    View PubMed
  4. Goetz MP, Suman VJ, Reid JM, Northfelt DW, Mahr MA, Ralya AT, Kuffel M, Buhrow SA, Safgren SL, McGovern RM, Black J, Dockter T, Haddad T, Erlichman C, Adjei AA, Visscher D, Chalmers ZR, Frampton G, Kipp BR, Liu MC, Hawse JR, Doroshow JH, Collins JM, Streicher H, Ames MM, Ingle JN. First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer. J Clin Oncol. 2017 Oct 20; 35 (30):3391-3400 Epub 2017 Aug 30
    View PubMed
  5. Leary SES, Park JR, Reid JM, Ralya AT, Baruchel S, Wu B, Roberts TPL, Liu X, Minard CG, Fox E, Weigel B, Blaney S. Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res. 2017 Oct 15; 23 (20):6062-6069 Epub 2017 July 27
    View PubMed
  6. Gingery A, Iwaniec UT, Subramaniam M, Turner RT, Pitel KS, McGovern RM, Reid JM, Marler RJ, Ingle JN, Goetz MP, Hawse JR. Skeletal and Uterotrophic Effects of Endoxifen in Female Rats. Endocrinology. 2017 Oct 01; 158 (10):3354-3368
    View PubMed
  7. Meredith CK, Widemann BC, Minard CG, Liu X, Kim A, Bernhardt B, Kudgus RA, Reid JM, Blaney S, Fox E, Weigel BJ. A Phase 1 Study of Cabozantinib in Children and Adolescents with Recurrent or Refractory Solid Tumors, Including CNS Tumors: A Report from the Children’s Oncology Group JCO.2017;
  8. Nevala WK, Buhrow SA, Knauer DJ, Reid JM, Atanasova EA, Markovic SN. Antibody-Targeted Chemotherapy for the Treatment of Melanoma. Cancer Res. 2016 Jul 01; 76 (13):3954-64 Epub 2016 Apr 28
    View PubMed
  9. Howe CL, LaFrance-Corey RG, Mirchia K, Sauer BM, McGovern RM, Reid JM, Buenz EJ. Neuroprotection mediated by inhibition of calpain during acute viral encephalitis. Sci Rep. 2016 Jun 27; 6:28699.
    View PubMed
  10. Camacho-Pereira J, Tarrago MG, Chini CCS, Nin V, Escande C, Warner GM, Puranik AS, Schoon RA, Reid JM, Galina A, Chini EN. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metab. 2016 Jun 14; 23 (6):1127-1139
    View PubMed
  11. Covey JM, Reid JM, Buhrow SA, Kuffel M, Walden C, Behrsing H, Ames MM. Comparative Metabolism of Batracylin (NSC 320846) and N-acetylbatracylin (NSC 611001) Using Human, Dog, and Rat Preparations In Vitro. J Drug Metab Toxicol. 2016 Jun; 7: (2).
    View PubMed
  12. Gupta SK, Kizilbash SH, Carlson BL, Mladek AC, Boakye-Agyeman F, Bakken KK, Pokorny JL, Schroeder MA, Decker PA, Cen L, Eckel-Passow JE, Sarkar G, Ballman KV, Reid JM, Jenkins RB, Verhaak RG, Sulman EP, Kitange GJ, Sarkaria JN. Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. J Natl Cancer Inst. 2016 May; 108 (5) Epub 2015 Nov 27
    View PubMed
  13. DuBois SG, Marachelian A, Fox E, Kudgus RA, Reid JM, Groshen S, Malvar J, Bagatell R, Wagner L, Maris JM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Matthay KK, Mosse YP. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. J Clin Oncol. 2016 Apr 20; 34: (12)1368-75.
    View PubMed
  14. Hooten WM, Nicholson WT, Gazelka HM, Reid JM, Moeschler SM, Lamer TJ. Serum Triamcinolone Levels Following Interlaminar Epidural Injection. Reg Anesth Pain Med. 2016 Jan-Feb; 41: (1)75-9.
    View PubMed
  15. Gustafson CT, Boakye-Agyeman F, Brinkman CL, Reid JM, Patel R, Bajzer Z, Dadsetan M, Yaszemski MJ. Controlled Delivery of Vancomycin via Charged Hydrogels. PLoS One. 2016; 11: (1)e0146401.
    View PubMed
  16. Berg AK, Buckner JC, Galanis E, Jaeckle KA, Ames MM, Reid JM. Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure. J Clin Pharmacol. 2015 Nov; 55: (11)1303-12.
    View PubMed
  17. Loh ML, Tasian SK, Rabin KR, Brown P, Magoon D, Reid JM, Chen X, Ahern CH, Weigel BJ, Blaney SM. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011). Pediatr Blood Cancer. 2015 Oct; 62: (10)1717-24.
    View PubMed
  18. Raetz EA, Cairo MS, Borowitz MJ, Lu X, Devidas M, Reid JM, Goldenberg DM, Wegener WA, Zeng H, Whitlock JA, Adamson PC, Hunger SP, Carroll WL. Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2. Pediatr Blood Cancer. 2015 Jul; 62: (7)1171-5.
    View PubMed
  19. Davis M, Bunin DI, Samuelsson SJ, Altera KP, Kinders RJ, Lawrence SM, Ji J, Ames MM, Buhrow SA, Walden C, Reid JM, Rausch LL, Parman T. Characterization of Batracylin-induced Renal and Bladder Toxicity in Rats. Toxicol Pathol. 2015 Jun; 43: (4)519-29.
    View PubMed
  20. Fouladi M, Perentesis JP, Wagner LM, Vinks AA, Reid JM, Ahern C, Thomas G, Mercer CA, Krueger DA, Houghton PJ, Doyle LA, Chen H, Weigel B, Blaney SM. A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res. 2015 Apr 01; 21: (7)1558-65.
    View PubMed
  21. Safgren SL, Suman VJ, Kosel ML, Gilbert JA, Buhrow SA, Black JL, Northfelt DW, Modak AS, Rosen D, Ingle JN, Ames MM, Reid JM, Goetz MP. Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen. Pharmacogenet Genomics. 2015 Apr; 25: (4)157-63.
    View PubMed
  22. Thompson MD, Grubbs CJ, Bode AM, Reid JM, McGovern R, Bernard PS, Stijleman IJ, Green JE, Bennett C, Juliana MM, Moeinpour F, Steele VE, Lubet RA. Lack of effect of metformin on mammary carcinogenesis in nondiabetic rat and mouse models. Cancer Prev Res (Phila). 2015 Mar; 8: (3)231-9.
    View PubMed
  23. Reid JM, Goetz MP, Buhrow SA, Walden C, Safgren SL, Kuffel MJ, Reinicke KE, Suman V, Haluska P, Hou X, Ames MM. Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies. Cancer Chemother Pharmacol. 2014 Dec; 74: (6)1271-8.
    View PubMed
  24. Schweikart KM, Eldridge SR, Safgren SL, Parman T, Reid JM, Ames MM, Goetz MP, Davis MA. Comparative uterotrophic effects of endoxifen and tamoxifen in ovariectomized Sprague-Dawley rats. Toxicol Pathol. 2014 Dec; 42: (8)1188-96.
    View PubMed
  25. Gupta SK, Mladek AC, Carlson BL, Boakye-Agyeman F, Bakken KK, Kizilbash SH, Schroeder MA, Reid J, Sarkaria JN. Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts. Clin Cancer Res. 2014 Jul 15; 20: (14)3730-41.
    View PubMed
  26. Kudgus RA, Walden CA, McGovern RM, Reid JM, Robertson JD, Mukherjee P. Tuning pharmacokinetics and biodistribution of a targeted drug delivery system through incorporation of a passive targeting component. Sci Rep. 2014 Jul 11; 4:5669.
    View PubMed
  27. Reid JM, Buhrow SA, Gilbert JA, Jia L, Shoji M, Snyder JP, Ames MM. Mouse pharmacokinetics and metabolism of the curcumin analog, 4-piperidinone,3,5-bis[(2-fluorophenyl)methylene]-acetate(3E,5E) (EF-24; NSC 716993). Cancer Chemother Pharmacol. 2014 Jun; 73: (6)1137-46.
    View PubMed
  28. Deming DA, Ninan J, Bailey HH, Kolesar JM, Eickhoff J, Reid JM, Ames MM, McGovern RM, Alberti D, Marnocha R, Espinoza-Delgado I, Wright J, Wilding G, Schelman WR. A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors. Invest New Drugs. 2014 Apr; 32: (2)323-9.
    View PubMed
  29. Weigel B, Malempati S, Reid JM, Voss SD, Cho SY, Chen HX, Krailo M, Villaluna D, Adamson PC, Blaney SM. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2014 Mar; 61(3):452-6. Epub 2013 Aug 17.
    View PubMed
  30. Fouladi M, Perentesis JP, Phillips CL, Leary S, Reid JM, Mcgovern RM, Ingle AM, Ahern CH, Ames MM, Houghton P, Doyle LA, Weigel B, Blaney SM. A phase I trial of MK-2206 in children with refractory malignancies: A Children's Oncology Group study. Pediatr Blood Cancer. 2014; 61(7):1246-51.
    View PubMed
  31. Schelman WR, Traynor AM, Holen KD, Kolesar JM, Attia S, Hoang T, Eickhoff J, Jiang Z, Alberti D, Marnocha R, Reid JM, Ames MM, McGovern RM, Espinoza-Delgado I, Wright JJ, Wilding G, Bailey HH. A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies. Invest New Drugs. 2013 Dec; 31(6):1539-46. Epub 2013 Oct 10.
    View PubMed
  32. Goetz MP, McKean HA, Reid JM, Mandrekar SJ, Tan AD, Kuffel MA, Safgren SL, McGovern RM, Goldberg RM, Grothey AA, McWilliams R, Erlichman C, Ames MM. UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine. Invest New Drugs. 2013 Dec; 31: (6)1559-67.
    View PubMed
  33. Thompson PA, Drissi R, Muscal JA, Panditharatna E, Fouladi M, Ingle AM, Ahern CH, Reid JM, Lin T, Weigel BJ, Blaney SM. A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL1112). Clin Cancer Res. 2013 Dec 1; 19: (23)6578-84.
    View PubMed
  34. Coats D, Frank EL, Reid JM, Ou K, Chea M, Khin M, Preou C, Enders FT, Fischer PR, Topazian M. Thiamine pharmacokinetics in Cambodian mothers and their breastfed infants. Am J Clin Nutr. 2013 Sep; 98(3):839-44. Epub 2013 Jul 17.
    View PubMed
  35. Hummel TR, Wagner L, Ahern C, Fouladi M, Reid JM, McGovern RM, Ames MM, Gilbertson RJ, Horton T, Ingle AM, Weigel B, Blaney SM. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study. Pediatr Blood Cancer. 2013 Sep; 60(9):1452-7. Epub 2013 Mar 28.
    View PubMed
  36. Glade Bender JL, Lee A, Reid JM, Baruchel S, Roberts T, Voss SD, Wu B, Ahern CH, Ingle AM, Harris P, Weigel BJ, Blaney SM. Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report. J Clin Oncol. 2013 Aug 20; 31(24):3034-43. Epub 2013 Jul 15
    View PubMed
  37. Holkova B, Supko JG, Ames MM, Reid JM, Shapiro GI, Perkins EB, Ramakrishnan V, Tombes MB, Honeycutt C, McGovern RM, Kmieciak M, Shrader E, Wellons MD, Sankala H, Doyle A, Wright J, Roberts JD, Grant S. A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. Clin Cancer Res. 2013 Apr 1; 19(7):1873-83. Epub 2013 Mar 20.
    View PubMed
  38. Berg AK, Mandrekar SJ, Ziegler KL, Carlson EC, Szabo E, Ames MM, Boring D, Limburg PJ, Reid JM, Cancer Prevention Network. Population pharmacokinetic model for cancer chemoprevention with sulindac in healthy subjects. J Clin Pharmacol. 2013 Apr; 53: (4)403-12.
    View PubMed
  39. Muscal JA, Thompson PA, Horton TM, Ingle AM, Ahern CH, McGovern RM, Reid JM, Ames MM, Espinoza-Delgado I, Weigel BJ, Blaney SM. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916). Pediatr Blood Cancer. 2013 Mar; 60(3):390-5. Epub 2012 Aug 09.
    View PubMed
  40. Kudgus RA, Szabolcs A, Khan JA, Walden CA, Reid JM, Robertson JD, Bhattacharya R, Mukherjee P. Inhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeutics. PLoS One. 2013; 8: (3)e57522.
    View PubMed
  41. Lee EQ, Puduvalli VK, Reid JM, Kuhn JG, Lamborn KR, Cloughesy TF, Chang SM, Drappatz J, Yung WK, Gilbert MR, Robins HI, Lieberman FS, Lassman AB, McGovern RM, Xu J, Desideri S, Ye X, Ames MM, Espinoza-Delgado I, Prados MD, Wen PY. Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Clin Cancer Res. 2012 Nov 1; 18(21):6032-9. Epub 2012 Aug 24.
    View PubMed
  42. Alberts SR, Reid JM, Morlan BW, Farr GH Jr, Camoriano JK, Johnson DB, Enger JR, Seay TE, Kim GP. Gemcitabine and docetaxel for hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trial. Am J Clin Oncol. 2012 Oct; 35: (5)418-23.
    View PubMed
  43. Bryce AH, Rao R, Sarkaria J, Reid JM, Qi Y, Qin R, James CD, Jenkins RB, Boni J, Erlichman C, Haluska P. Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors. Invest New Drugs. 2012 Oct; 30: (5)1934-41.
    View PubMed
  44. Glade Bender, Blaney SM, Borinstein S, Reid JM, Baruchel S, Ahern C, Ingle AM, Yamashiro DJ, Chen A, Weigel B, Adamson PC, Park JR. A phase I trial and pharmacokinetic study of Aflibercept (VEGF Trap) in children with refractory solid tumors: a Children's Oncology Group Phase I Consortium report. Clin Cancer Res. 2012 Sep 15; 18(18):5081-9. Epub 2012 Jul 12.
    View PubMed
  45. DuBois SG, Shusterman S, Reid JM, Ingle AM, Ahern CH, Baruchel S, Glade-Bender J, Ivy P, Adamson PC, Blaney SM. Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study. Cancer Chemother Pharmacol. 2012 Apr; 69(4):1021-7. Epub 2011 Dec 18.
    View PubMed
  46. Malempati S, Weigel B, Ingle AM, Ahern CH, Carroll JM, Roberts CT, Reid JM, Schmechel S, Voss SD, Cho SY, Chen HX, Krailo MD, Adamson PC, Blaney SM. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2012 Jan 20; 30(3):256-62. Epub 2011 Dec 19.
    View PubMed
  47. Kaufmann SH, Karp JE, Litzow MR, Mesa RA, Hogan W, Steensma DP, Flatten KS, Loegering DA, Schneider PA, Peterson KL, Maurer MJ, Smith BD, Greer J, Chen Y, Reid JM, Ivy SP, Ames MM, Adjei AA, Erlichman C, Karnitz LM. Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia. Haematologica. 2011 Nov; 96: (11)1619-26.
    View PubMed
  48. Villablanca JG, London WB, Naranjo A, McGrady P, Ames MM, Reid JM, McGovern RM, Buhrow SA, Jackson H, Stranzinger E, Kitchen BJ, Sondel PM, Parisi MT, Shulkin B, Yanik GA, Cohn SL, Reynolds CP. Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group. Clin Cancer Res. 2011 Nov 1; 17(21):6858-66. Epub 2011 Sep 09.
    View PubMed
  49. Dickson MA, Rathkopf DE, Carvajal RD, Grant S, Roberts JD, Reid JM, Ames MM, McGovern RM, Lefkowitz RA, Gonen M, Cane LM, Dials HJ, Schwartz GK. A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors. Invest New Drugs. 2011 Oct; 29(5):1004-12. Epub 2010 May 12.
    View PubMed
  50. Reid JM, Buhrow SA, Kuffel MJ, Jia L, Spanswick VJ, Hartley JA, Thurston DE, Tomaszewski JE, Ames MM. Pharmacokinetics, pharmacodynamics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136 in rats. Cancer Chemother Pharmacol. 2011 Sep; 68 (3):777-86 Epub 2010 Dec 28
    View PubMed
  51. Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, Jia L, Weil M, Speranza G, Murgo AJ, Kinders R, Wang L, Parchment RE, Carter J, Stotler H, Rubinstein L, Hollingshead M, Melillo G, Pommier Y, Bonner W, Tomaszewski JE, Doroshow JH. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res. 2011 Sep 1; 71(17):5626-34. Epub 2011 Jul 27.
    View PubMed
  52. Dubois SG, Shusterman S, Ingle AM, Ahern CH, Reid JM, Wu B, Baruchel S, Glade-Bender J, Ivy P, Grier HE, Adamson PC, Blaney SM. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study. Clin Cancer Res. 2011 Aug 1; 17(15):5113-22. Epub 2011 Jun 20.
    View PubMed
  53. Muscal JA, Thompson PA, Horton TM, Ingle AM, Ahern CH, McGovern RM, Reid JM, Ames MM, Weigel B, Blaney S. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group study. J Clin Oncol. 2011 May 20; 29: (15_suppl)9522.
    View PubMed
  54. Goetz MP, Reid JM, Qi Y, Chen A, McGovern RM, Kuffel MJ, Scanlon PD, Erlichman C, Ames MM. A phase I study of once-weekly aminoflavone prodrug (AFP464) in solid tumor patients. J Clin Oncol. 2011 May 20; 29: (15_suppl)2546.
    View PubMed
  55. Wen PY, Puduvalli VK, Kuhn JG, Reid JM, Lamborn K, Cloughesy TF, Chang SM, Drappatz J, Yung WK, Gilbert MR, Robins HI, Lieberman FS, Lassman AB, McGovern RM, Desideri S, Ye X, Ames MM, Espinoza-Delgado IJ, Grossman SA, Prados M. Phase I study of vorinostat in combination with temozolomide in patients with malignant gliomas. J Clin Oncol. 2011 May 20; 29: (15_suppl)2032.
    View PubMed
  56. Reid JM, Walden CA, Qin R, Ziegler KL, Haslam JL, Rajewski RA, Warndahl R, Fitting CL, Boring D, Szabo E, Crowell J, Perloff M, Jong L, Bauer BA, Mandrekar SJ, Ames MM, Limburg PJ, Cancer Prevention Network. Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668. Cancer Prev Res (Phila). 2011 Mar; 4: (3)347-53.
    View PubMed
  57. Pruthi S, Haakenson C, Brost BC, Bryant K, Reid JM, Singh R, Netzel B, Boughey JC, Degnim AC. Pharmacokinetics of methylene blue dye for lymphatic mapping in breast cancer-implications for use in pregnancy. Am J Surg. 2011 Jan; 201(1):70-5.
    View PubMed
  58. Arvizo RR, Miranda OR, Moyano DF, Walden CA, Giri K, Bhattacharya R, Robertson JD, Rotello VM, Reid JM, Mukherjee P. Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. PLoS One. 2011; 6: (9)e24374.
    View PubMed
  59. George RE, Lahti JM, Adamson PC, Zhu K, Finkelstein D, Ingle AM, Reid JM, Krailo M, Neuberg D, Blaney SM, Diller L. Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2010 Oct; 55(4):629-38.
    View PubMed
  60. Jaeckle KA, Ballman KV, Giannini C, Schomberg PJ, Ames MM, Reid JM, McGovern RM, Safgren SL, Galanis E, Uhm JH, Brown PD, Hammack JE, Arusell R, Nikcevich DA, Morton RF, Wender DB, Buckner JC. Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM. J Neurooncol. 2010 Aug; 99: (1)73-80.
    View PubMed
  61. Fouladi M, Park JR, Stewart CF, Gilbertson RJ, Schaiquevich P, Sun J, Reid JM, Ames MM, Speights R, Ingle AM, Zwiebel J, Blaney SM, Adamson PC. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol. 2010 Aug 1; 28(22):3623-9. Epub 2010 Jul 06.
    View PubMed
  62. Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD, Ingle AM, Blaney SM, Adamson PC. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study. Pediatr Blood Cancer. 2010 Apr; 54(4):538-45.
    View PubMed
  63. Litzow MR, Peethambaram PP, Safgren SL, Keeney GL, Ansell SM, Dispenzieri A, Elliott MA, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Micallef IN, Porrata LF, Lingle WL, Hartmann LC, Frost MH, Barrette BA, Long HJ, Suman VJ, Reid JM, Ames MM, Kaufmann SH. Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma. Bone Marrow Transplant. 2010 Mar; 45: (3)490-7.
    View PubMed
  64. Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD, Ingle AM, Blaney SM, Adamson PC. Phase I trial and pharmacokinetic study of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with refractory solid tumors: A Children's Oncology Group Phase I Consortium study. J Clin Oncol. 2009 May 20; 27: (15_suppl)10017.
    View PubMed
  65. Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, Reilly JF, Loboda A, Nebozhyn M, Fantin VR, Richon VM, Scheithauer B, Giannini C, Flynn PJ, Moore DF Jr, Zwiebel J, Buckner JC. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol. 2009 Apr 20; 27: (12)2052-8.
    View PubMed
  66. Santisteban M, Buckner JC, Reid JM, Wu W, Scheithauer BW, Ames MM, Felten SJ, Nikcevich DA, Wiesenfeld M, Jaeckle KA, Galanis E, North Central Cancer Treatment Group. Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results. J Neurooncol. 2009 Apr; 92: (2)165-75.
    View PubMed
  67. Molina JR, Kaufmann SH, Reid JM, Rubin SD, Galvez-Peralta M, Friedman R, Flatten KS, Koch KM, Gilmer TM, Mullin RJ, Jewell RC, Felten SJ, Mandrekar S, Adjei AA, Erlichman C. Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data. Clin Cancer Res. 2008 Dec 01; 14: (23)7900-8.
    View PubMed
  68. Bradley KA, Pollack IF, Reid JM, Adamson PC, Ames MM, Vezina G, Blaney S, Ivy P, Zhou T, Krailo M, Reaman G, Mehta MP, Children's Oncology Group. Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study. Neuro Oncol. 2008 Oct; 10(5):752-8. Epub 2008 Aug 20
    View PubMed
  69. Raetz EA, Cairo MS, Borowitz MJ, Blaney SM, Krailo MD, Leil TA, Reid JM, Goldenberg DM, Wegener WA, Carroll WL, Adamson PC, Children's Oncology Group Pilot Study. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol. 2008 Aug 1; 26(22):3756-62.
    View PubMed
  70. Horton TM, Ames MM, Reid JM, Krailo MD, Pendergrass T, Mosher R, Reaman GH, Seibel NL, Children's Oncology Group. A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children's Oncology Group study. Pediatr Blood Cancer. 2008 Apr; 50(4):788-92.
    View PubMed
  71. Patra CR, Bhattacharya R, Wang E, Katarya A, Lau JS, Dutta S, Muders M, Wang S, Buhrow SA, Safgren SL, Yaszemski MJ, Reid JM, Ames MM, Mukherjee P, Mukhopadhyay D. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res. 2008 Mar 15; 68(6):1970-8.
    View PubMed
  72. Reid JM, Mandrekar SJ, Carlson EC, Harmsen WS, Green EM, McGovern RM, Szabo E, Ames MM, Boring D, Limburg PJ, Cancer Prevention Network. Comparative bioavailability of sulindac in capsule and tablet formulations. Cancer Epidemiol Biomarkers Prev. 2008 Mar; 17: (3)674-9.
    View PubMed
  73. Bender JLG, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, Kerbel RS, Cooney-Qualter EM, Stempak D, Chen HX, Nelson MD, Krailo MD, Ingle AM, Blaney SM, Kandel JJ, Yamashiro DJ. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: A children's oncology group study. J Clin Oncol. 2008 Jan 20; 26(3):399-405.
    View PubMed
  74. Furth AF, Mandrekar SJ, Tan AD, Rau A, Felten SJ, Ames MM, Adjei AA, Erlichman C, Reid JM. A limited sample model to predict area under the drug concentration curve for 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomycin. Cancer Chemother Pharmacol. 2008 Jan; 61(1):39-45. Epub 2007 Mar 20.
    View PubMed
  75. Jia L, Schweikart K, Tomaszewski J, Page JG, Noker PE, Buhrow SA, Reid JM, Ames MM, Munn DH. Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption. Food Chem Toxicol. 2008 Jan; 46(1):203-11. Epub 2007 Aug 10.
    View PubMed
  76. Patra CR, Cao S, Safgren S, Bhattacharya R, Ames MM, Shah V, Reid JM. Intracellular fate of a targeted delivery system. J. Biomed. Nanotechnol. 2008; 4(4):508-14.
    View PubMed
  77. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007 Dec; 114(12):2179-82.
    View PubMed
  78. Myers RM, Greiner SM, Harvey ME, Griesmann G, Kuffel MJ, Buhrow SA, Reid JM, Federspiel M, Ames MM, Dingli D, Schweikart K, Welch A, Dispenzieri A, Peng KW, Russell SJ. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther. 2007 Dec; 82: (6)700-10.
    View PubMed
  79. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007 May; 114(5):855-9.
    View PubMed
  80. Malempati S, Nicholson HS, Reid JM, Blaney SM, Ingle AM, Krailo M, Stork LC, Melemed AS, McGovern R, Safgren S, Ames MM, Adamson PC, Children's Oncology Group. Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group. J Clin Oncol. 2007 Apr 20; 25(12):1505-11.
    View PubMed
  81. Weigel BJ, Blaney SM, Reid JM, Safgren SL, Bagatell R, Kersey J, Neglia JP, Ivy SP, Ingle AM, Whitesell L, Gilbertson RJ, Krailo M, Ames M, Adamson PC. A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study. Clin Cancer Res. 2007 Mar 15; 13(6):1789-93.
    View PubMed
  82. Stapleton SL, Reid JM, Thompson PA, Ames MM, McGovern RM, McGuffey L, Nuchtern J, Dauser R, Blaney SM. Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates. Cancer Chemother Pharmacol. 2007 Mar; 59(4):461-6.
    View PubMed
  83. Ma C, Mandrekar SJ, Alberts SR, Croghan GA, Jatoi A, Reid JM, Hanson LJ, Bruzek L, Tan AD, Pitot HC, Erlichman C, Wright JJ, Adjei AA. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies. Cancer Chemother Pharmacol. 2007 Feb; 59(2):207-15. Epub 2006 Jun 9
    View PubMed
  84. Reid J, Safgren S, Rios R, Rajkumar S, Buckner J, Ames M. Pharmacokinetics of dacarbazine and its active metabolites MTIC and HMMTIC in patients with recurrent glioma Clin Cancer Res. 2007.
    View PubMed
  85. Henzing AJ, Dodson H, Reid JM, Kaufmann SH, Baxter RL, Earnshaw WC. Synthesis of novel caspase inhibitors for characterization of the active caspase proteome in vitro and in vivo. J Med Chem. 2006 Dec 28; 49(26):7636-45.
    View PubMed
  86. Nowakowski GS, McCollum AK, Ames MM, Mandrekar SJ, Reid JM, Adjei AA, Toft DO, Safgren SL, Erlichman C. A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res. 2006 Oct 15; 12: (20 Pt 1)6087-93.
    View PubMed
  87. Buhrow SA, Reid JM, Jia L, McGovern RM, Covey JM, Kobs DJ, Grossi IM, Ames MM. LC-MS/MS assay and dog pharmacokinetics of the dimeric pyrrolobenzodiazepine SJG-136 (NSC 694501). J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Aug 7; 840(1):56-62. Epub 2006 May 24.
    View PubMed
  88. Pitot HC, Adjei AA, Reid JM, Sloan JA, Atherton PJ, Rubin J, Alberts SR, Duncan BA, Denis L, Schaaf LJ, Yin D, Sharma A, McGovren P, Miller LL, Erlichman C. A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2006 Aug; 58: (2)165-72.
    View PubMed
  89. Children's Oncology Group (CCG 09709), Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH, Reynolds CP. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). J Clin Oncol. 2006 Jul 20; 24(21):3423-30.
    View PubMed
  90. Delaunoit T, Burch PA, Reid JM, Camoriano JK, Kobayash T, Braich TA, Kaur JS, Rubin J, Erlichman C. A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors. Invest New Drugs. 2006 Jul; 24 (4):327-33
    View PubMed
  91. Ballman KV, Jaeckle KA, Schomberg P, Giannini C, Galanis E, Brown P, Arusell R, Reid J, Hammack J, Buckner J. Phase II trial of irinotecan (CPT-11) and radiation followed by irinotecan and BCNU in glioblastoma patients (pts). J Clin Oncol. 2006 Jun 20; 24: (18_suppl)1562.
    View PubMed
  92. Glade Bender JL, Adamson PC, Baruchel S, Shaked Y, Chen HX, Reid JM, Ingle AM, Blaney SM, Kandel JJ, Yamashiro DJ. A phase I study of bevacizumab in children with refractory solid tumors: A Children's Oncology Group study. J Clin Oncol. 2006 Jun 20; 24: (18_suppl)9017.
    View PubMed
  93. Weigel B, Blaney S, Kersey J, Bagatell R, Ivy SP, Whitesell L, Krailo M, Reid J, Ames M, Adamson P. A phase I study of 17-AAG in relapsed/refractory pediatric patients with solid tumors: A Children's Oncology Groups study. J Clin Oncol. 2006 Jun 20; 24: (18_suppl)9018.
    View PubMed
  94. Wakelee HA, Adjei AA, Halsey J, Lensing JL, Dugay JD, Hanson LJ, Reid JM, Piens JR, Sikic BI. A phase I dose-escalation and pharmacokinetic (PK) study of a novel spectrum selective kinase inhibitor, XL647, in patients with advanced solid malignancies (ASM). J Clin Oncol. 2006 Jun 20; 24: (18_suppl)3044.
    View PubMed
  95. Whitlock JA, Krailo M, Reid JM, Ruben SL, Ames MM, Owen W, Reaman G, Children's Oncology Group Study. Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2005 Dec 20; 23(36):9179-86.
    View PubMed
  96. Galanis E, Buckner JC, Maurer MJ, Reid JM, Kuffel MJ, Ames MM, Scheithauer BW, Hammack JE, Pipoly G, Kuross SA. Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial. Invest New Drugs. 2005 Oct; 23 (5):495-503
    View PubMed
  97. Molina JR, Reid JM, Erlichman C, Sloan JA, Furth A, Safgren SL, Lathia CD, Alberts SR. A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin. Anticancer Drugs. 2005 Oct; 16(9):997-1002.
    View PubMed
  98. Kaufmann SH, Karp JE, Letendre L, Kottke TJ, Safgren S, Greer J, Gojo I, Atherton P, Svingen PA, Loegering DA, Litzow MR, Sloan JA, Reid JM, Ames MM, Adjei AA, Erlichman C. Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia. Clin Cancer Res. 2005 Sep 15; 11(18):6641-9.
    View PubMed
  99. Bible KC, Lensing JL, Nelson SA, Lee YK, Reid JM, Ames MM, Isham CR, Piens J, Rubin SL, Rubin J, Kaufmann SH, Atherton PJ, Sloan JA, Daiss MK, Adjei AA, Erlichman C. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin Cancer Res. 2005 Aug 15; 11(16):5935-41.
    View PubMed
  100. Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, Hanson L, DeLuca P, Bruzek L, Piens J, Asbury P, Van Becelaere K, Herrera R, Sebolt-Leopold J, Meyer MB. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol. 2005 Aug 10; 23(23):5281-93. Epub 2005 Jul 11.
    View PubMed
  101. Dy GK, Suri A, Reid JM, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Atherton PJ, Hanson LJ, Burch PA, Rubin J, Erlichman C, Adjei AA. A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors. Cancer Chemother Pharmacol. 2005 Jun; 55(6):522-30. Epub 2005 Mar 08.
    View PubMed
  102. Ma CX, Croghan G, Reid J, Hanson L, Mandrekar S, Marks R, Adjei A, Furth A. A phase I trial of the combination of erlotinib and tipifarnib in patients with advanced solid tumors. J Clin Oncol. 2005 Jun; 23: (16_suppl)3000.
    View PubMed
  103. Wakelee H, Adjei AA, Keer H, Halsey J, Hanson L, Reid J, Hutchison S, Piens J, Lacy S, Sikic BI. A phase I dose-escalation and pharmacokinetic (PK) study of a novel multiple-targeted receptor tyrosine kinase (RTK) inhibitor, XL647, in patients with advanced solid malignancies. J Clin Oncol. 2005 Jun; 23: (16_suppl)3142.
    View PubMed
  104. Goetz MP, Safgren S, Goldberg RM, Grothey AF, Mandrekar SJ, Reid JM, Erlichman C, Adjei AA, Rubin J, Ames MM. A phase I dose escalation study of irinotecan (CPT-11), oxaliplatin (Oxal), and capecitabine (Cap) within three UGT1A1 TA promoter cohorts (6/6, 6/7, and 7/7). J Clin Oncol. 2005 Jun; 23: (16_suppl)2014.
    View PubMed
  105. Dy GK, Bruzek LM, Croghan GA, Mandrekar S, Erlichman C, Peethambaram P, Pitot HC, Hanson LJ, Reid JM, Furth A, Cheng S, Martell RE, Kaufmann SH, Adjei AA. A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer. Clin Cancer Res. 2005 Mar 1; 11(5):1877-83.
    View PubMed
  106. Goetz MP, Toft D, Reid J, Ames M, Stensgard B, Safgren S, Adjei AA, Sloan J, Atherton P, Vasile V, Salazaar S, Adjei A, Croghan G, Erlichman C. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol. 2005 Feb 20; 23(6):1078-87.
    View PubMed
  107. Erlichman C, Toft D, Reid J, Goetz M, Ames M, Mandrekar S, Ajei A, McCollum A, Ivy P. A phase I trial of 17-allylamino-geldanamycin (17AAG) in patients with advanced cancer. J Clin Oncol. 2004 Jul 15; 22: (14_suppl)3030.
    View PubMed
  108. Rao RD, Reid JM, Goetz MP, Furth AF, Mandrekar SJ, Adjei AA, Ames MM, Safgren SL, Erlichman C, Pitot HC. Phase I trial of OSI-774 and CPT-11 in patients with advanced solid tumors. J Clin Oncol. 2004 Jul 15; 22: (14_suppl)3053.
    View PubMed
  109. Reid JM, Qu W, Safgren SL, Ames MM, Krailo MD, Seibel NL, Kuttesch J, Holcenberg J. Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors. J Clin Oncol. 2004 Jun 15; 22(12):2445-51.
    View PubMed
  110. Reid JM, Walker DL, Miller JK, Benson LM, Tomlinson AJ, Naylor S, Blajeski AL, LoRusso PM, Ames MM. The metabolism of pyrazoloacridine (NSC 366140) by cytochromes p450 and flavin monooxygenase in human liver microsomes. Clin Cancer Res. 2004 Feb 15; 10(4):1471-80.
    View PubMed
  111. Reid JM, Walker DL, Naylor S, Benson LM, LaRusso PM, Ames MM. Metabolism of pyrazoloacridine (NSC-366140) by humans and mice: Identification and cytotoxicity of the urinary metabolites 9-desmethylpyrazoloacridine and pyrazoloacridine-N-oxide. Clin. Cancer Res.. 2004; 10: 1471-80.
  112. Goetz MP, Erlichman C, Windebank AJ, Reid JM, Sloan JA, Atherton P, Adjei AA, Rubin J, Pitot H, Galanis E, Ames MM, Goldberg RM. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors. J Clin Oncol. 2003 Oct 15; 21: (20)3761-9.
    View PubMed
  113. Adjei AA, Croghan GA, Erlichman C, Marks RS, Reid JM, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Bruzek LM, Atherton P, Thibault A, Palmer PA, Kaufmann SH. A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res. 2003 Jul; 9: (7)2520-6.
    View PubMed
  114. Reid JM, Squillace DP, Ames MM. Single-dose pharmacokinetics of the DNA-binding bioreductive agent NLCQ-1 (NSC 709257) in CD2F1 mice. Cancer Chemother Pharmacol. 2003 Jun; 51(6):483-7. Epub 2003 Apr 25.
    View PubMed
  115. Buckner JC, Reid JM, Wright K, Kaufmann SH, Erlichman C, Ames M, Cha S, O'Fallon JR, Schaaf LJ, Miller LL. Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group. Cancer. 2003 May 01; 97: (9 Suppl)2352-8.
    View PubMed
  116. Adjei AA, Dy GK, Erlichman C, Reid JM, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Atherton PJ, Watanabe T, Geary RS, Holmlund J, Dorr FA. A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin Cancer Res. 2003 Jan; 9(1):115-23.
    View PubMed
  117. Klein CE, Gupta E, Reid JM, Atherton PJ, Sloan JA, Pitot HC, Ratain MJ, Kastrissios H. Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide. Clinical Pharmacology & Therapeutics. 2002 Dec; 72(6):638-47.
    View PubMed
  118. Steinherz PG, Seibel NL, Ames MM, Avramis VI, Krailo MD, Liu-Mares W, Reid JM, Safgren SL, Reaman GH. Phase I study of gemcitabine (difluorodeoxycytidine) in children with relapsed or refractory leukemia (CCG-0955): a report from the Children's Cancer Group. Leuk Lymphoma. 2002 Oct; 43(10):1945-50.
    View PubMed
  119. Reid JM, Kuffel MJ, Ruben SL, Morales JJ, Rinehart KL, Squillace DP, Ames MM. Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans. Clin Cancer Res. 2002 Sep; 8: (9)2952-62.
    View PubMed
  120. Adjei AA, Reid JM, Erlichman C, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Ruben S, Boemer SA, Atherton P, Ames MM, Kaufmann SH. A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer. Invest New Drugs. 2002 Aug; 20 (3):297-304
    View PubMed
  121. Kuffel MJ, Schroeder JC, Pobst LJ, Naylor S, Reid JM, Kaufmann SH, Ames MM. Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1/1A2. Mol Pharmacol. 2002 Jul; 62(1):143-53.
    View PubMed
  122. Adjei AA, Reid JM, Diasio RB, Sloan JA, Smith DA, Rubin J, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Atherton P, Ames MM, Erlichman C. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. J Clin Oncol. 2002 Mar 15; 20: (6)1683-91.
    View PubMed
  123. Pitot HC, Reid JM, Sloan JA, Ames MM, Adjei AA, Rubin J, Bagniewski PG, Atherton P, Rayson D, Goldberg RM, Erlichman C. A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors. Clin Cancer Res. 2002 Mar; 8(3):712-7.
    View PubMed
  124. Wells RJ, Reid JM, Ames MM, Mares WL, Krailo MD, Seibel NL, Mosher R, Reaman GH, Wiersma SR. Phase I trial of cisplatin and topotecan in children with recurrent solid tumors: Children's Cancer Group Study 0942. J Pediatr Hematol Oncol. 2002 Feb; 24(2):89-93.
    View PubMed
  125. Darkes MJM, Plosker GL, Jarvis, B.(Various sections reviewed by: SD'Atri HS Friedman, LA Hammond, MR Middleton, JM Reid, K Warren). Temozolomide, A review of its use in the treatment of malignant gliomas, malignant melanoma and other advanced cancers. Am. J. Cancer. 2002; 1:55-80.
  126. Sloan JA, Atherton P, Reid J, Pitot HC, Erlichman C, Schaaf L. Limited sampling models for CPT-11, SN-38, and SN-38 glucuronide. Cancer Chemother Pharmacol. 2001 Sep; 48: (3)241-9.
    View PubMed
  127. Galanis E, Goldberg R, Reid J, Atherton P, Sloan J, Pitot H, Rubin J, Adjei AA, Burch P, Safgren SL, Witzig TE, Ames MM, Erlichman C. Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2'-deoxyuridine (IdUrd). Ann Oncol. 2001 May; 12: (5)701-7.
    View PubMed
  128. Safgren SL, Reid JM, Rios R, Ames MM. Validated high-performance liquid chromatographic assay for simultaneous determination of dacarbazine and the plasma metabolites 5-(3-hydroxymethyl-3-methyl-1-triazeno)imidazole-4-carboxamide and 5-(3-methyl-1-triazeno)imidazole-4-carboxamide. J Chromatogr B Biomed Sci Appl. 2001 Apr 15; 754(1):91-6.
    View PubMed
  129. Bracho F, Krailo MD, Shen V, Bergeron S, Davenport V, Liu-Mares W, Blazar BR, Panoskaltsis-Mortari A, van de Ven C, Secola R, Ames MM, Reid JM, Reaman GH, Cairo MS. A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities. Clin Cancer Res. 2001 Jan; 7(1):58-67.
    View PubMed
  130. Safgren SL, Reid JM, Rios R, Ames MM. Validated HPLC assay for simultaneous determination of dacarbazine and the plasma metabolites 5-(3-hydrxoymethyl-3-methyl-1-triazeno)imidazole-4-carboxamide and 5-(3-methyl-1-triazeno)imidazole-4-carboxamide. J. Chromatogr.. 2001; 754: 91-6.
  131. Rajkumar SV, Reid JM, Novotny PJ, Safgren SL, Scheithauer BW, Johnson PS, Nair S, Morton RF, Hatfield AK, Krook JE, Ames MM, Buckner JC, North Central Cancer Treatment Group. A randomized phase II and pharmacokinetic study of dacarbazine in patients with recurrent glioma. J Neurooncol. 2000 Sep; 49 (3):255-61
    View PubMed
  132. Pitot HC, Goldberg RM, Reid JM, Sloan JA, Skaff PA, Erlichman C, Rubin J, Burch PA, Adjei AA, Alberts SA, Schaaf LJ, Elfring G, Miller LL. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. Clin Cancer Res. 2000 Jun; 6: (6)2236-44.
    View PubMed
  133. Adjei AA, Erlichman C, Sloan JA, Reid JM, Pitot HC, Goldberg RM, Peethambaram P, Atherton P, Hanson LJ, Alberts SR, Jett J. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol. 2000 Apr; 18: (8)1748-57.
    View PubMed
  134. Adjei AA, Klein CE, Kastrissios H, Goldberg RM, Alberts SR, Pitot HC, Sloan JA, Reid JM, Hanson LJ, Atherton P, Rubin J, Erlichman C. Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity. J Clin Oncol. 2000 Mar; 18: (5)1116-23.
    View PubMed
  135. Mruk JS, Webster MW, Heras M, Reid JM, Grill DE, Chesebro JH. Flavone-8-acetic acid (Flavonoid) profoundly reduces platelet-dependent thrombosis and vasoconstriction after deep arterial injury In vivo. Circulation. 2000 Jan 25; 101(3):324-8.
    View PubMed
  136. Adjei AA, Klein CE, Kastrissious H, Goldberg RM, Sloan JA, Alberts SR, Pitot H, Reid JM, Hanson L, Atherton-Skaff P, Rubin J, Erlichman C. A Phase I study of irinotecan and docetaxel in patients with advanced solid tumors: Preliminary evidence of clinical activity. J. Clin. Oncol.. 2000; 18: 1116-23.
  137. Frangoul H, Ames MM, Mosher RB, Reid JM, Krailo MD, Seibel NL, Shaw DWW, Steinherz PG, Whitlock JA, Holcenberg JS. Phase I study of topotecan administered as a 21-day continuous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group. Clin Cancer Res. 1999 Dec; 5(12):3956-3962.
    View PubMed
  138. Walker DL, Reid JM, Svingen PA, Rios R, Covey JM, Alley MC, Hollingshead MG, Budihardjo II, Eckdahl S, Boerner SA, Kaufmann SH, Ames MM. Murine pharmacokinetics of 6-aminonicotinamide (NSC 21206), a novel biochemical modulating agent. Biochem Pharmacol. 1999 Sep 15; 58(6):1057-66.
    View PubMed
  139. Reid JM, Kuffel MJ, Miller JK, Rios R, Ames MM. Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. Clin Cancer Res. 1999 Aug; 5(8):2192-7.
    View PubMed
  140. Pitot HC, McElroy EA Jr, Reid JM, Windebank AJ, Sloan JA, Erlichman C, Bagniewski PG, Walker DL, Rubin J, Goldberg RM, Adjei AA, Ames MM. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res. 1999 Mar; 5(3):525-31.
    View PubMed
  141. Buckner JC, Malkin MG, Reed E, Cascino TL, Reid JM, Ames MM, Tong WP, Lim S, Figg WD. Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. Mayo Clin Proc. 1999 Feb; 74: (2)137-45.
    View PubMed
  142. Berg SL, Reid J, Godwin K, Murry DJ, Poplack DG, Balis FM, Ames MM. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. J Pediatr Hematol Oncol. 1999 Jan-Feb; 21(1):26-30.
    View PubMed
  143. Rajkumar SV, Buckner JC, Schomberg PJ, Reid JM, Bagniewski PJ, Ames MM, Cascino TL, Marks RS. Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma. Int J Radiat Oncol Biol Phys. 1998 Dec 1; 42(5):969-75.
    View PubMed
  144. Alberts SR, Erlichman C, Reid JM, Sloan JA, Ames MM, Richardson RL, Goldberg RM. Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks. Clin Cancer Res. 1998 Sep; 4(9):2111-7.
    View PubMed
  145. Nicholson HS, Krailo M, Ames MM, Seibel NL, Reid JM, Liu-Mares W, Vezina LG, Ettinger AG, Reaman GH. Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children's Cancer Group. J Clin Oncol. 1998 Sep; 16(9):3037-43.
    View PubMed
  146. Adjei AA, Charron M, Rowinsky EK, Svingen PA, Miller J, Reid JM, Sebolt-Leopold J, Ames MM, Kaufmann SH. Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II. Clin Cancer Res. 1998 Mar; 4(3):683-91.
    View PubMed
  147. Budihardjo II, Walker DL, Svingen PA, Buckwalter CA, Desnoyers S, Eckdahl S, Shah GM, Poirier GG, Reid JM, Ames MM, Kaufmann SH. 6-Aminonicotinamide sensitizes human tumor cell lines to cisplatin. Clin Cancer Res. 1998 Jan; 4(1):117-30.
    View PubMed
  148. Reid JM, Kovach JS, O'Connell MJ, Bagniewski PG, Moertel CG. Clinical and pharmacokinetic studies of high-dose levamisole in combination with 5-fluorouracil in patients with advanced cancer. Cancer Chemother Pharmacol. 1998; 41: (6)477-84.
    View PubMed
  149. Budihardjo II, Walker DL, Svingen PA, Buckwalter CA, Desnoyers S, Shah GM, Poirier GG, Reid JM, Ames MM, Kaufmann SH. 6-Aminonicotinamide increases cisplatin sensitivity by increasing formation of platinum-DNA adducts. Clin. Cancer Res.. 1998; 4: 117-30.
  150. Goldberg RM, Reid JM, Ames MM, Sloan JA, Rubin J, Erlichman C, Kuffel MJ, Fitch TR. Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor. Clin Cancer Res. 1997 Dec; 3(12 Pt 1):2363-70.
    View PubMed
  151. Reid JM, Stevens DC, Rubin J, Ames MM. Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer. Clin Cancer Res. 1997 Dec; 3: (12 Pt 1)2393-8.
    View PubMed
  152. Lawrence JB, Conover CA, Haddad TC, Ingle JN, Reid JM, Ames MM, Suman VJ, Marks RS, Erlichman C, Hartmann LC. Evaluation of continuous infusion suramin in metastatic breast cancer: impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding proteins. Clin Cancer Res. 1997 Oct; 3(10):1713-20.
    View PubMed
  153. Dhodapkar M, Rubin J, Reid JM, Burch PA, Pitot HC, Buckner JC, Ames MM, Suman VJ. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res. 1997 Jul; 3: (7)1093-100.
    View PubMed
  154. Feig SA, Ames MM, Sather HN, Steinherz L, Reid JM, Trigg M, Pendergrass TW, Warkentin P, Gerber M, Leonard M, Bleyer WA, Harris RE. Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group. Med Pediatr Oncol. 1996 Dec; 27(6):505-14.
    View PubMed
  155. Reid JM, Walker DL, Ames MM. Preclinical pharmacology of ecteinascidin 729, a marine natural product with potent antitumor activity. Cancer Chemother Pharmacol. 1996; 38(4):329-34.
    View PubMed
  156. Hartmann LC, Ames MM, Reid JM, Richardson RL. Phase I trial of diaziquone (AZQ) plus GM-CSF. Invest New Drugs. 1995; 13 (2):175-6
    View PubMed
  157. Reid JM, Benson JW, Viallet J, Ames MM. Preclinical pharmacology of cholera toxin. Cancer Chemother Pharmacol. 1995; 36: (2)115-20.
    View PubMed
  158. Tefferi A, Witzig TE, Reid JM, Li CY, Ames MM. Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma. J Clin Oncol. 1994 Mar; 12: (3)569-74.
    View PubMed
  159. Walker DL, Reid JM, Ames MM. Preclinical pharmacology of bizelesin, a potent bifunctional analog of the DNA-binding antibiotic CC-1065. Cancer Chemother Pharmacol. 1994; 34: (4)317-22.
    View PubMed
  160. Dhodapkar MV, Richardson RL, Reid JM, Ames MM. Pyrazine diazohydroxide (NSC-361456). Phase I clinical and pharmacokinetic studies. Invest New Drugs. 1994; 12 (3):207-16
    View PubMed
  161. Tefferi A, Silverstein MN, Plumhoff EA, Reid JM, Ames MM. Suramin toxicity and efficacy in agnogenic myeloid metaplasia. J Natl Cancer Inst. 1993 Sep 15; 85(18):1520-2.
    View PubMed
  162. Blaney SM, Balis FM, Cole DE, Craig C, Reid JM, Ames MM, Krailo M, Reaman G, Hammond D, Poplack DG. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res. 1993 Mar 1; 53(5):1032-6.
    View PubMed
  163. Benson LM, Tomlinson AJ, Reid JM, Walker DL, Ames MM, Naylor S. In vivo pyrazoloacridine metabolism by capillary electrophoresis using isotachophoresis preconcentration in non-aqueous separation buffer. J High Resolut Chromatogr. 1993; 16:324-326.
  164. Reid JM, Mathiesen DA, Bensen LM, Kuffel MJ, Ames MM. Murine pharmacokinetics and metabolism of penclomedine (3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl)pyridine, NSC 338720). Cancer Res. 1992 May 15; 52:2830-2834.
    View PubMed
  165. Kuffel MJ, Reid JM, Ames MM. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother Pharmacol. 1992; 30: (1)51-7.
    View PubMed
  166. Ames MM, Mathiesen DA, Reid JM. Differences in N-acetylation of the experimental antitumor agent batracylin in the mouse and the rat. Invest New Drugs. 1991 Aug; 9 (3):219-25
    View PubMed
  167. Reid JM, Pendergrass TW, Krailo MD, Hammond GD, Ames MM. Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report. Cancer Res. 1990 Oct 15; 50(20):6525-8.
    View PubMed
  168. Reid JM, Stobaugh JF, Sternson LA. Liquid chromatographic determination of cyclophosphamide enantiomers in plasma by precolumn chiral derivatization. Anal Chem. 1989 Mar 1; 61(5):441-6.
    View PubMed
  169. Sternson LA, Stobaugh JF, Reid J, DeMontigny P. Chemical derivatization as a strategy to enhance detectability of agents used in cancer management. J Pharm Biomed Anal. 1988; 6:657-668.
    View PubMed